NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ — Alcresta Therapeutics, Inc., a primary business-stage company targeted on creating and commercializing novel, enzyme-centered merchandise, now declared the appointment of Alan Muney, MD to its Board of Directors. Dr. Muney is at this time a senior health care advisor for Pritzker Private Capital, Arsenal Capital, Bain Administration Consulting, and NEA Venture Capital.
“I truly feel privileged to be associated with these kinds of a gifted workforce dedicated to the mission of bringing a terrific know-how to market to support chronically sick individuals,” explained Dr. Muney.
Earlier Dr. Muney served as Cigna’s Chief Clinical Officer and Government Vice President of Total Health and fitness and Community. In his purpose as Chief Medical Officer, Dr. Muney was responsible for Cigna’s scientific method and plan, well being advocacy courses, coverage plan, and high quality measurement and improvement. As guide for Overall Overall health and Community, Dr. Muney was accountable for the sector health-related and clinical nurse executives, overall wellness medical professional functions, total well being scientific operations, and dental medical operations, as perfectly as health-related, behavioral, and dental contracting. Dr. Muney also oversaw Cigna’s staff of medical professionals, dentists, nurses, and behavioral health and fitness clinicians concerned in the firm’s well being administration and wellness systems.
Right before joining Cigna, Dr. Muney was Government Director in the Private Equity Group at The Blackstone Group, and CEO of Equity Health care, which he launched to regulate the healthcare expenditures of Blackstone’s portfolio providers. Even though at Blackstone, he also served on the Board of Directors of Vanguard Health Technique and Crew Health and fitness. Prior to Blackstone, Alan was Executive Vice President and Chief Medical Officer of Oxford Wellness Plans and Chief Professional medical Officer of United Healthcare of the Northeast region from 1998-2007.
Mr. Muney is board-certified in pediatrics and obtained his B.S. in Biology and his Medical professional of Medicine levels from Brown University, and a Masters in Wellness Administration from the College of La Verne.
“We are delighted to welcome Dr. Muney,” stated Dan Orlando, Chief Government Officer of Alcresta. “His extensive expertise as a board-certified pediatrician, an government at a countrywide payer, and an advisor to leading healthcare investment decision corporations will make Dr. Muney a precious addition to Alcresta’s Board of Administrators.”
About Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. is devoted to building and commercializing novel enzyme-primarily based products and solutions built to tackle challenges confronted by men and women living with gastrointestinal problems and rare health conditions. The organization employs its proprietary engineering system to aid a wide pipeline of merchandise, with an preliminary focus on pancreatic insufficiency, which benefits in malabsorption typical in cystic fibrosis, digestive cancers, untimely delivery, and other serious conditions. Alcresta Therapeutics, Inc. at this time markets RELiZORB®, a 1st-of-its form digestive enzyme cartridge that mimics the operate of pancreatic lipase to crack down fats into extra absorbable fatty acids. Dependent in Massachusetts, Alcresta Therapeutics, Inc. is backed by top-tier undertaking traders: Athyrium Cash Management, Wellbeing Quest Funds, Bessemer Venture Companions, Frazier Healthcare Partners, and Third Rock Ventures. For extra information and facts, remember to go to www.alcresta.com.
RELiZORB, iLipase, the Alcresta capstone, and Alcresta Therapeutics are registered emblems of Alcresta Therapeutics, Inc. All legal rights reserved.
Alcresta Media Speak to:
Daniel Orlando
Chief Govt Officer
617-431-3585
[email protected]
Supply Alcresta Therapeutics, Inc.
